RCS - Physiomics PLC - New Services Launch and Website Update

PhysiomicsAnnouncement

02/10/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241002:nRSB5442Ga&default-theme=true

RNS Number : 5442G  Physiomics PLC  02 October 2024

2 October 2024

 

Physiomics plc

("Physiomics" or the "Company")

 

New Services Launch and Website Update

 

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science
company supporting the development of new therapeutics and personalised
medicine solutions, is pleased to announce the official launch of its
Biostatistics offering and expansion of its Data Science and Bioinformatics
services.

Leveraging its existing expertise and capabilities across the core Modelling
and Simulation service line, the Company is moving forward to expand its
offering into the synergistic service areas of Biostatistics and Data Science;
both of which play crucial roles in drug development.

 

Biostatistics:

Biostatistics is an essential component of clinical research. It plays a
pivotal role in the setup, conduct and reporting of all trials, regardless of
therapeutic area, ensuring studies are well designed, data is accurately
collected and analysed, and the results are interpreted correctly. For
example, during the design of interventional trials, biostatistics is used to
calculate the optimum number of patients to be recruited and help define what
data should be collected so that the effect of the therapy can be detected,
balancing this against the size and cost of the trial.

The strategic rationale for Physiomics to develop the new Biostatistics
services is three-fold. Firstly, the application of Modelling & Simulation
and Biostatistics in drug development overlaps, with often the output of the
former being a key input to the latter, allowing for natural follow-on work to
be offered to clients. Secondly, biostatistics is a necessary component to the
setup, conduct and reporting of any interventional clinical trial, from Phase
1 through to Phase 4, regardless of the therapeutic area. This opens a
significant market for the Company, giving greater opportunity to scale.
Finally, with both service lines utilising the same business model and similar
expertise across mathematics and data science, this allows the Company to
operate flexible staffing across service lines to meet demand and maximise
utilisation.

 

Data Science and Bioinformatics:

Data Science and Bioinformatics have also become critical capabilities across
the drug development continuum. From discovery through into the clinic, the
volume and complexity of data being generated is increasing significantly,
driven in part by advancements in technologies and regulatory pressures. Being
able to effectively make use of this often-disparate data and derive insights
from it is often where the challenge lies for drug developers. Data science
and Bioinformatics tools and methodologies allow for the effective selection,
curation, analysis and visualisation of this data.

The Company has already been leveraging Data Science and Bioinformatics tools
and methodologies as part of its core Modelling and Simulation service line,
selecting and curating data required to develop and calibrate its models. The
opportunity to use these tools and models outside Modelling and Simulation has
become more apparent, with the Company delivering on its first pure Data
Science and Bioinformatics project earlier in the year. During this project,
the Company supported the client capture and curated a wide range of publicly
available data relating to novel oncology drug targets. The data was processed
and then presented in a form that allowed the client to determine the optimum
drug target across a variety of tissue types. Physiomics is keen to build upon
this success and identify new opportunities in this space.

 

Launch:

As of 30 September 2024, Physiomics has officially launched its new
Biostatistics offering, as well as its expanded offering in Data Science and
Bioinformatics, allowing the Company to offer a more integrated offering to
its clients. To coincide with this, the Company has completed an update of its
website (www.physiomics.co.uk (http://www.physiomics.co.uk) ) and marketing
materials to support a variety of go-to-market activities and campaigns over
the coming weeks.

 

Dr Peter Sargent, CEO, commented: "We are delighted to have launched the new
Biostatistics service line, as well as expand our Data Science and
Bioinformatics Services. Not only can we now provide our clients a great
breadth of services to support their drug development efforts, but these new
services are an important component of the Company's growth strategy."

 

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines cutting edge PKPD and QSP modelling and data science
techniques, along with deep biology expertise, to help biotech and pharma
companies streamline their drug development journeys.

 

Our approach is to derive insight from all relevant data in order to de-risk
decision making and optimise design research across discovery, pre-clinical
and clinical studies.

 

Through use of bespoke models and our proprietary Virtual Tumour technology,
the Physiomics team has informed the development of over 100 commercial
projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas,
Bicycle Therapeutics, Numab Therapeutics & CRUK.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAQKDBQABDDAKK